Matthew J. Kan

Matthew J. Kan

Auto-generated profile, based on publicly available information

Matthew J. Kan

Innovative Genomics Institute, University of California , Berkeley , CA 94720, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2015 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
MKMatthew J. Kan
Matthew J. Kan
JLJennifer E. Lee
Jennifer E. Lee
JWJoan G. Wilson
Joan G. Wilson
AEAngela L. Everhart
Angela L. Everhart
Candice M. BrownCandice M. Brown
Candice M. Brown
CCCarol A. Colton
Carol A. Colton
The pathogenesis of Alzheimer's disease (AD) is a critical unsolved question; and although recent studies have demonstrated a strong association between altered brain immune responses and disease progression, the mechanistic cause of neuronal dysfunction and death is unknown. We have previously described the unique CVN-AD mouse model of AD, in which immune-mediated nitric oxide is lowered to mimic human levels, resulting in a mouse model that demonstrates the cardinal features of AD, including amyloid deposition, hyperphosphorylated and aggregated tau, behavioral changes, and age-dependent hippocampal neuronal loss. Using this mouse model, we studied longitudinal changes in brain immunity in relation to neuronal loss and, contrary to the predominant view that AD pathology is driven by proinflammatory factors, we find that the pathology in CVN-AD mice is driven by local immune suppression. Areas of hippocampal neuronal death are associated with the presence of immunosuppressive CD11c+microglia and extracellular arginase, resulting in arginine catabolism and reduced levels of total brain arginine. Pharmacologic disruption of the arginine utilization pathway by an inhibitor of arginase and ornithine decarboxylase protected the mice from AD-like pathology and significantly decreased CD11c expression. Our findings strongly implicate local immune-mediated amino acid catabolism as a novel and potentially critical mechanism mediating the age-dependent and regional loss of neurons in humans with AD.

15 March 2020 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
YYYen-Rei A Yu
Yen-Rei A Yu
YMYuryi Malakhau
Yuryi Malakhau
CYChen-Hsin A Yu
Chen-Hsin A Yu
SPStefan-Laural J. Phelan
Stefan-Laural J. Phelan
RCR. Ian Cumming
R. Ian Cumming
MGMichael D. Gunn
Michael D. Gunn
An increasing body of evidence suggests that bone marrow–derived myeloid cells play a critical role in the pathophysiology of pulmonary hypertension (PH). However, the true requirement for myeloid cells in PH development has not been demonstrated, and a specific disease-promoting myeloid cell population has not been identified. Using bone marrow chimeras, lineage labeling, and proliferation studies, we determined that, in murine hypoxia-induced PH, Ly6Clo nonclassical monocytes are recruited to small pulmonary arteries and differentiate into pulmonary interstitial macrophages. Accumulation of these nonclassical monocyte–derived pulmonary interstitial macrophages around pulmonary vasculature is associated with increased muscularization of small pulmonary arteries and disease severity. To determine if the sensing of hypoxia by nonclassical monocytes contributes to the development of PH, mice lacking expression of hypoxia-inducible factor-1α in the Ly6Clo monocyte lineage were exposed to hypoxia. In these mice, vascular remodeling and PH severity were significantly reduced. Transcriptome analyses suggest that the Ly6Clo monocyte lineage regulates PH through complement, phagocytosis, Ag presentation, and chemokine/cytokine pathways. Consistent with these murine findings, relative to controls, lungs from pulmonary arterial hypertension patients displayed a significant increase in the frequency of nonclassical monocytes. Taken together, these findings show that, in response to hypoxia, nonclassical monocytes in the lung sense hypoxia, infiltrate small pulmonary arteries, and promote vascular remodeling and development of PH. Our results demonstrate that myeloid cells, specifically cells of the nonclassical monocyte lineage, play a direct role in the pathogenesis of PH. Key Points Ly6Clo nonclassical monocytes infiltrate the pulmonary vasculature and promote PH. Hif1α regulates the maturation of nonclassical monocytes into infiltrating IMØ. Infiltrating IMØ promote PH by modulating local immune and cytokine responses.

27 October 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
BABenjamin A Adler
Benjamin A Adler
MTMarena I Trinidad
Marena I Trinidad
DRDaniel Bellieny Rabelo
Daniel Bellieny Rabelo
EZElaine Zhang
Elaine Zhang
HKHannah M Karp
Hannah M Karp
JDJennifer A Doudna
Jennifer A Doudna
CRISPR-Cas enzymes enable RNA-guided bacterial immunity and are widely used for biotechnological applications including genome editing. In particular, the Class 2 CRISPR-associated enzymes (Cas9, Cas12 and Cas13 families), have been deployed for numerous research, clinical and agricultural applications. However, the immense genetic and biochemical diversity of these proteins in the public domain poses a barrier for researchers seeking to leverage their activities. We present CasPEDIA (http://caspedia.org), the Cas Protein Effector Database of Information and Assessment, a curated encyclopedia that integrates enzymatic classification for hundreds of different Cas enzymes across 27 phylogenetic groups spanning the Cas9, Cas12 and Cas13 families, as well as evolutionarily related IscB and TnpB proteins. All enzymes in CasPEDIA were annotated with a standard workflow based on their primary nuclease activity, target requirements and guide-RNA design constraints. Our functional classification scheme, CasID, is described alongside current phylogenetic classification, allowing users to search related orthologs by enzymatic function and sequence similarity. CasPEDIA is a comprehensive data portal that summarizes and contextualizes enzymatic properties of widely used Cas enzymes, equipping users with valuable resources to foster biotechnological development. CasPEDIA complements phylogenetic Cas nomenclature and enables researchers to leverage the multi-faceted nucleic-acid targeting rules of diverse Class 2 Cas enzymes.

26 October 2026 in Genetics in Medicine
Verified
Journal Article
Closed access
NGNina Gold
Nina Gold
BJBritt A. Johnson
Britt A. Johnson
HSHarini Somanchi
Harini Somanchi
TMThomas Minten
Thomas Minten
SCStephanie A. Coury
Stephanie A. Coury
RGRobert C. Green
Robert C. Green